Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.

Hundertmark MJ. et al, (2023), Circulation

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

Bethel MA. et al, (2023), Cardiovasc Diabetol, 22

Association of osteocalcin, osteoprotegerin and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes.

Maddaloni E. et al, (2023), Diabetes Metab Res Rev

11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.

Othonos N. et al, (2023), Nat Commun, 14

Teplizumab approval for type 1 diabetes in the USA.

Beran D. et al, (2023), Lancet Diabetes Endocrinol, 11, 78 - 80

Joint longitudinal and time-to-event modeling compared with standard Cox modeling in patients with type 2 diabetes with and without established cardiovascular disease: an analysis of the EXSCEL trial.

Oulhaj A. et al, (2023), Diabetes Obes Metab

Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials

Maddaloni E. et al, (2023), Diabetes, Obesity and Metabolism

Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)

Green JB. et al, (2023), Diabetes, Obesity and Metabolism

Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.

Shields BM. et al, (2022), Nat Med

Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.

Shields BM. et al, (2022), Nat Med

Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - Authors' reply.

Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 841 - 842

Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.

Dennis JM. et al, (2022), Lancet Digit Health, 4, e873 - e883

Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events.

Regan JA. et al, (2022), Sci Rep, 12

Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol.

Butterly E. et al, (2022), BMJ Open, 12

TriMaster: randomised double-blind crossover trial of a DPP4-inhibitor, SGLT2-inhibitor and thiazolidinedione to evaluate differential glycaemic response to therapy based on obesity and renal function

Hattersley A. et al, (2022)

Endpoints and estimands: understanding trials of weight-loss drugs.

Adler AI., (2022), Nat Med, 28, 2005 - 2006

How can we optimise health technology assessment and reimbursement decisions to accelerate access to new cardiovascular medicines?

Cowie MR. et al, (2022), International journal of cardiology, 365, 61 - 68

Risk prediction models for incident type 2 diabetes in Chinese people with intermediate hyperglycemia: a systematic literature review and external validation study.

Xu S. et al, (2022), Cardiovasc Diabetol, 21

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.

Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 645 - 654

Diabetes remission by weight loss in 'normal' weight people with type 2 diabetes: the ReTUNE study

Taylor R. et al, (2022), DIABETOLOGIA, 65, S135 - S135

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?